A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma

Trial Profile

A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2012

At a glance

  • Drugs Veltuzumab (Primary)
  • Indications B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Immunomedics
  • Most Recent Events

    • 18 May 2009 Results have been published online in the Journal of Clinical Oncology; announed by Immunomedics in a media release.
    • 21 Jan 2008 Status changed from in progresss to completed.
    • 18 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top